Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS
· Delayed Price · Currency is USD
0.0850
-0.0210 (-19.81%)
Mar 9, 2026, 1:37 PM EST
Inhibitor Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 2.98 | 5.61 | 8.84 | 11.95 | 0.03 | 0.08 | Upgrade
|
| Cash & Short-Term Investments | 2.98 | 5.61 | 8.84 | 11.95 | 0.03 | 0.08 | Upgrade
|
| Cash Growth | -53.33% | -36.57% | -26.03% | 38923.13% | -59.20% | -90.66% | Upgrade
|
| Prepaid Expenses | 0.09 | 0.09 | 0.11 | 0.02 | 0.03 | 0.03 | Upgrade
|
| Total Current Assets | 3.06 | 5.69 | 8.95 | 11.98 | 0.06 | 0.11 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | - | 0.02 | Upgrade
|
| Total Assets | 3.14 | 5.69 | 8.95 | 11.98 | 0.06 | 0.13 | Upgrade
|
| Accounts Payable | 0.02 | 0.02 | 0.03 | 0.15 | 0.28 | 0.27 | Upgrade
|
| Accrued Expenses | 0.04 | 0.69 | 0.63 | 0.12 | 0.07 | - | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | 0.41 | 0.23 | 0.03 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 0.1 | 0.13 | Upgrade
|
| Total Current Liabilities | 0.09 | 0.71 | 0.67 | 0.68 | 0.68 | 0.43 | Upgrade
|
| Long-Term Debt | - | - | - | - | - | 0.07 | Upgrade
|
| Long-Term Unearned Revenue | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Total Liabilities | 3.13 | 3.71 | 3.67 | 3.68 | 3.68 | 3.49 | Upgrade
|
| Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 54.11 | 54.09 | 54.05 | 54.03 | 50.05 | 49.81 | Upgrade
|
| Retained Earnings | -54.12 | -52.12 | -48.78 | -45.75 | -57.67 | -57.17 | Upgrade
|
| Total Common Equity | 0 | 1.99 | 5.28 | 8.3 | -7.58 | -7.32 | Upgrade
|
| Shareholders' Equity | 0 | 1.99 | 5.28 | 8.3 | -3.62 | -3.36 | Upgrade
|
| Total Liabilities & Equity | 3.14 | 5.69 | 8.95 | 11.98 | 0.06 | 0.13 | Upgrade
|
| Total Debt | 0.07 | - | - | 0.41 | 0.23 | 0.1 | Upgrade
|
| Net Cash (Debt) | 2.91 | 5.61 | 8.84 | 11.54 | -0.2 | -0.02 | Upgrade
|
| Net Cash Growth | -54.45% | -36.57% | -23.40% | - | - | - | Upgrade
|
| Net Cash Per Share | 0.02 | 0.03 | 0.05 | 0.03 | -0.00 | -0.00 | Upgrade
|
| Filing Date Shares Outstanding | 172.57 | 172.32 | 172.02 | 171.79 | 376.86 | 375.88 | Upgrade
|
| Total Common Shares Outstanding | 172.57 | 172.32 | 172.02 | 171.79 | 376.86 | 373.64 | Upgrade
|
| Working Capital | 2.98 | 4.99 | 8.28 | 11.3 | -0.62 | -0.32 | Upgrade
|
| Book Value Per Share | 0.00 | 0.01 | 0.03 | 0.05 | -0.02 | -0.02 | Upgrade
|
| Tangible Book Value | 0 | 1.99 | 5.28 | 8.3 | -7.58 | -7.32 | Upgrade
|
| Tangible Book Value Per Share | 0.00 | 0.01 | 0.03 | 0.05 | -0.02 | -0.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.